peptide elongation factor 2 has been researched along with Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, LE; Chung, D; Hurst, KE; Lawrence, KA; Robino, RA; Thaxton, JE | 1 |
| Bardy, C; Désaubry, L; Jiang, T; Jin, X; Proud, CG; Wang, D; Wang, X; Xie, J; Zabolocki, M | 1 |
| Dieffenbach, M; Pastan, I | 1 |
| Agnihotri, S; Ahern, CA; Barokas, A; Bowden, M; Bridon, G; Collins, VP; Delattre, O; Derry, WB; Dubuc, A; El-Naggar, A; Faubert, B; Galpin, JD; Gleave, ME; Hielscher, T; Jan, E; Jones, RG; Kool, M; Korshunov, A; Kwok, B; Leprivier, G; Li, A; Mateo, AR; Mathers, J; McCabe, MG; Northcott, PA; Pfister, SM; Pollak, M; Proud, CG; Remke, M; Rotblat, B; Smith, S; Somasekharan, SP; Sorensen, PH; Taylor, MD; Thomas, R; Tognon, CE; Wang, Y; Wu, X; Yu, B | 1 |
| Cheng, H; Liu, J; Lu, J; Qin, Q; Sun, X; Xu, L; Yang, X; Zhan, L; Zhang, C; Zhou, L; Zhu, H | 1 |
| Li, J; Qi, X; Wang, GZ | 1 |
| De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L | 1 |
| Kurtz, DT; Voelkel-Johnson, C; White-Gilbertson, S | 1 |
| Bui, MH; Chen, Z; Donnelly, JB; Glaser, KB; Gopalakrishnan, SM; Johnson, EF; Soni, NB; Warrior, U | 1 |
| Muthukumar, Y; Raja, A; Roy, M; Sasse, F; Taylor, RE | 1 |
| Almasan, A; Huang, LC; Linke, SP; Paulson, TG; Wahl, GM | 1 |
4 review(s) available for peptide elongation factor 2 and Neoplasms
| Article | Year |
|---|---|
Mechanisms of Resistance to Immunotoxins Containing
Topics: ADP Ribose Transferases; Bacterial Toxins; Cell Survival; Clinical Trials as Topic; Cytosol; Drug Resistance, Neoplasm; Exotoxins; Humans; Immunotoxins; Neoplasms; Peptide Elongation Factor 2; Protein Transport; Pseudomonas aeruginosa Exotoxin A; Virulence Factors | 2020 |
Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
Topics: Apoptosis; Autophagy; Elongation Factor 2 Kinase; Gene Silencing; Humans; Neoplasms; Peptide Elongation Factor 2; Up-Regulation | 2015 |
The role of protein synthesis in cell cycling and cancer.
Topics: Cell Cycle; Cell Line, Tumor; Elongation Factor 2 Kinase; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasms; Peptide Elongation Factor 2; Protein Biosynthesis; Survivin | 2009 |
Genetic instability as a consequence of inappropriate entry into and progression through S-phase.
Topics: Animals; Antimetabolites; Apoptosis; Cell Transformation, Neoplastic; Chromosome Aberrations; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; G1 Phase; Gene Expression Regulation; Genes, p53; Genes, Retinoblastoma; Genome; Humans; Mutation; Neoplasms; Peptide Elongation Factor 2; Peptide Elongation Factors; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; S Phase; Tumor Suppressor Protein p53 | 1995 |
7 other study(ies) available for peptide elongation factor 2 and Neoplasms
| Article | Year |
|---|---|
Remodeling Translation Primes CD8
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Female; Immunotherapy; Interleukin-15; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Neoplasms; Peptide Elongation Factor 2; Protein Biosynthesis | 2020 |
The prohibitin-binding compound fluorizoline affects multiple components of the translational machinery and inhibits protein synthesis.
Topics: A549 Cells; Calcium; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; HEK293 Cells; HeLa Cells; Humans; Neoplasm Proteins; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Prohibitins; Protein Biosynthesis; Protein Synthesis Inhibitors; Repressor Proteins | 2020 |
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Caenorhabditis elegans; Cell Survival; Cell Transformation, Neoplastic; Elongation Factor 2 Kinase; Food Deprivation; Glioblastoma; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Peptide Chain Elongation, Translational; Peptide Elongation Factor 2; Signal Transduction; Transplantation, Heterologous | 2013 |
[Eukaryotic elongation factor 2 kinase and cancer].
Topics: Elongation Factor 2 Kinase; Humans; Neoplasms; Peptide Elongation Factor 2; Phosphorylation | 2015 |
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden | 2016 |
1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; eIF-2 Kinase; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
The marine polyketide myriaporone 3/4 stalls translation by targeting the elongation phase.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bryozoa; Cell Line; Cell Line, Tumor; Cell Proliferation; Elongation Factor 2 Kinase; Epoxy Compounds; Humans; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; Pyrans | 2013 |